Psoriatic Arthritis (PsA) Treatment Market

The global Psoriatic Arthritis (PsA) Treatment market size was USD 22.11 billion in 2023, and is calculated at USD 24.01 Billion in 2024. The market is projected to reach USD 50.45 Billion by 2034, and register a revenue 8.6% over the forecast period (2025-2034).

Premium Insights:

Global Psoriatic Arthritis (PsA) Treatment market has been registering steady incline in revenue growth, primarily driven by rising prevalence of arthritis and increasing patient awareness about the conditions and treatments. Also, demand for effective biologic and biosimilar therapies has also been rising significantly more recently, due to the efficacy new therapies have been exhibiting in managing PsA symptoms and slowing disease progression. Innovations in drug delivery, such as self-administered injectables, are also enhancing treatment accessibility and convenience, further driving adoption rates. In addition, significant investments in Research and Development (R&D) are leading to the introduction of novel therapies with fewer side effects and improved patient outcomes.

Furthermore, increasing availability of advanced diagnostic tools is enabling early PsA detection, thereby facilitating timely intervention and improving treatment success. Supportive government policies, especially in high-prevalence regions, are boosting access to PsA medications and therapies, and this is contributing to market growth. Telemedicine and online pharmaceutical sales have also been gaining traction, and patients now have easier access to treatments and consultations, which has contributed to wider treatment uptake. Additionally, rising healthcare expenditure and rapidly aging population with need to address incline in prevalence of age-related diseases and conditions across different regions are expected to continue to support growth of the global PsA treatment market over the forecast period.

PsA is a part of the spondyloarthritis complex, which also includes ankylosing spondylitis, reactive arthritis, and arthritis associated with inflammatory bowel disease. Symptoms of PsA include severe pain, swelling, and tenderness in joints. The exact cause of PsA however remains unclear, but both genetic and environmental factors are believed to contribute. While symptoms can develop at any age, individuals aged between 30 and 50 years indicate higher likelihood to be affected. Common symptoms include joint pain, swelling, and stiffness, often accompanied by psoriatic skin lesions, and this disease can lead to irreversible joint damage and disability if left untreated.

The global prevalence of psoriatic arthritis is 112 per 100,000 adults, but prevalence varies by region, with higher rates in Europe and North America than in Asia and South America. Populations-based studies indicate that estimated prevalence of PsA was 113 per 100,000 with continent-specific estimates of 207 (Europe), 64 (North America), and 37 (Asia) per 100,000.

Top Psoriatic Arthritis (PsA) Treatment Market Drivers and Trends:

• Rising Prevalence and Patient Awareness: Steady increase in global prevalence of psoriatic arthritis and rising awareness regarding the various treatment options available are primary factors driving market growth. Increasing number of patients are opting for early diagnosis and effective treatment to manage symptoms and prevent disease progression, which is driving demand for PsA therapies. Also, public health initiatives and educational programs continue to emphasize the importance of recognizing PsA symptoms early, and this is also a factor expected to support higher adoption rates of available treatments.
• Advancements in Biologic and Biosimilar Therapies: Significant progress in biologic and biosimilar medications is serving to open avenues for patients to access highly effective treatment options with fewer side effects than traditional drugs. These therapies are designed to target specific inflammatory pathways associated with PsA, making them a preferred choice among healthcare providers and patients. Also, demand for these therapies is expected to grow as demonstration and proof of positive outcomes become more known and reach wider patient bases and pools. This can also result in increased accessibility and easier affordability through biosimilar competition.
• Increased Investment in Research and Development: Extensive R&D activities in PsA treatment are resulting in a continuous pipeline of innovative products, further enhancing market growth. Pharmaceutical companies are focusing on developing advanced therapies that offer improved efficacy, more convenient administration methods - like subcutaneous and oral delivery - and better quality of life for patients. These advancements cater to a growing need for safe, effective treatments and are pivotal in broadening the range of offerings in the PsA treatment market.
• Expanding Telemedicine and Digital Health Solutions: Rising popularity of telemedicine and online pharmacies has simplified access to PsA treatments, especially in underserved regions. Patients now have greater flexibility in obtaining prescriptions and consulting specialists, which encourages adherence to treatment plans and drives higher demand for PsA medications. As digital health solutions become more sophisticated and widely available, the role in facilitating and supporting PsA treatment will likely continue to expand, and support market growth.

Psoriatic Arthritis (PsA) Treatment Market Restraining Factor Insights

• High Treatment Costs and Limited Insurance Coverage: The cost of biologics and advanced therapies for PsA remains a significant barrier for many patients, particularly in regions with limited insurance coverage or high out-of-pocket expenses. This financial burden can deter patients from seeking recommended treatments, especially when alternative and more affordable options are unavailable. Consequently, high treatment costs limit access and adoption, potentially slowing market revenue growth as patients delay or forego effective therapies.
• Potential Side Effects and Safety Concerns: While biologics and advanced PsA treatments offer efficacy benefits, they also carry risks of side effects such as immune system suppression and increased susceptibility to infections. Concerns regarding these adverse effects can discourage some patients from using certain medications, and they may opt instead for less effective but safer treatments. Ongoing challenges in reducing these side effects through R&D remain an obstacle, as companies work to develop safer alternatives that patients can use over the long term.
• Delayed Diagnosis and Low Awareness in Emerging Markets: Despite rising awareness globally, PsA often goes undiagnosed or misdiagnosed, especially in regions with limited healthcare resources and specialist availability. In emerging markets, lack of awareness among both patients and general practitioners about PsA symptoms and treatment options results in delayed or inappropriate care, limiting treatment uptake. This trend, along with gaps in infrastructure, could restrain market growth by preventing early intervention and diminishing patient demand for advanced therapies in these areas.

Psoriatic Arthritis (PsA) Treatment Market Opportunities

• Advancements in Innovative Biologics and Biosimilars: Development and commercialization of innovative biologics and biosimilars remain lucrative avenues for companies to leverage and generate additional revenue. These products can be designed and formulated to address critical gaps in efficacy and patient tolerance, and by enhancing affordability and accessibility, particularly with biosimilars, companies can tap into new revenue streams, meeting patient needs in both developed and emerging markets.
• Mergers, Acquisitions, and Partnerships: Engaging in strategic mergers, acquisitions, and partnerships with biotechnology firms and research institutions can present opportunities in the global market. Collaborations can expedite the R&D of next-generation PsA treatments and help expand product portfolios, enabling firms to leverage advanced technology and new insights. These alliances can also support market expansion into regions where PsA treatment options are currently limited.
• Leveraging Digital Health Solutions: Investment in digital health solutions such as telemedicine platforms for remote consultations can increase treatment accessibility and improve patient engagement. Companies offering support through digital tools can enhance patient adherence and boost long-term demand for PsA therapies. This can also present avenues to create additional revenue streams.

Psoriatic Arthritis (PsA) Treatment Market Segmentation:

By Drug Class:

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Biologics and Biosimilars
• Corticosteroids
• Others (PDE4 Inhibitors)

By Type of Treatment:

• Prescription-based
• Over-the-Counter (OTC)

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Segment Insights:

By Drug Class:

Among the drug class segments, the biologics and biosimilars segment is expected to account for largest revenue share over the forecast period. This projection is attributed to the advantages of targeted approach in treating PsA, and offer of more effective symptom management and disease modification compared to traditional treatments like NSAIDs and conventional DMARDs. Biologics target specific inflammatory processes linked to PsA, leading to improved outcomes and patient quality of life. Also, increasing availability of biosimilars as affordable alternatives to branded biologics is easing accessibility to these treatments, especially in cost-sensitive markets. Rising patient awareness and physician preference for biologics due to safety and efficacy profiles further contribute to their growing adoption and revenue share.

By Type of Treatment:

Among the type of treatment segments, the prescription-based segment is expected to maintain dominance in terms of revenue share over the forecast period. Prescription drugs, particularly biologics and DMARDs, are essential in managing moderate to severe cases of PsA. Administration requires physician oversight for effective and safe use, particularly due to potential side effects and interactions. Prescription-based treatments are typically covered under healthcare plans, improving affordability and accessibility for patients needing long-term care. The trend toward precision medicine, coupled with the need for specialist-prescribed, tailored treatment plans, is expected to continue to support demand for prescription-based therapies, and drive growth of this segment.

By Route of Administration:

Among the route of administration segments, the injectable segment accounted for largest revenue share in 2023. Injectables, particularly biologics, are more preferred for moderate to severe PsA due to rapid onset and direct action. Self-administered injectables and auto-injector devices have made it more convenient for patients to manage treatments from home, boosting adherence rates. Also, new developments in injection technology and devices are enhancing the patient experience, and reducing the frequency of doses and associated discomfort. Injectable route offers high bioavailability and efficiency, and continuous innovation in administration methods are expected to result in more convenience and support growth of this segment.

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

By Distribution Channel:

Among the distribution channel segments, the hospital pharmacies segment is expected to continue to account for largest revenue share over the forecast period. Large revenue share of this segment is due to the need for specialist consultation and monitoring for PsA treatments, particularly for advanced therapies like biologics, which may require prescription and professional administration. Patients often rely on hospital settings for accurate diagnosis, dosage adjustments, and management of potential side effects. Hospital pharmacies also serve as a centralized distribution channel for advanced therapies and complex PsA treatments, ensuring safe and regulated access. Also, provision of immediate access to specialized medications and patient education further positions hospitals as a leading channel.

Regions and Countries

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India

Rest of Asia Pacific

• Latin America
• Brazil
• Argentina

Rest of Latin America

• Middle East & Africa
• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA

Psoriatic Arthritis (PsA) Treatment Market Regional Landscape:

Among the regional markets in 2023, North America led in terms of revenue share due to high prevalence of PsA, strong healthcare infrastructure, and extensive R&D efforts. The US dominated the other country-level markets in North America in 2023, owing to major companies such as AbbVie, Pfizer, and Amgen being headquartered in the country and high focus on innovative biologic therapies to meet regional demand.

In Europe, countries such as Germany, the UK, and France lead in terms of adoption of various treatments and therapies, supported by favorable healthcare policies and high diagnostic rates. Also, presence of companies such as Novartis and others serve to enhance availability of advanced treatment solutions tailored to needs of the region.

Asia Pacific market is expected to register a rapid growth rate over the forecast period, driven by rising disease awareness, expanding healthcare access, and government support, especially in China, Japan, and India. Many global companies are increasing investments in countries in the region, while local firms are developing cost-effective treatments to meet the diverse demands of these large, emerging markets.

Psoriatic Arthritis (PsA) Treatment Market Competitive Landscape:

Company List:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Pfizer Inc.
• Bristol-Myers Squibb
• Novartis AG
• UCB S.A.
• Eli Lilly and Company
• Biogen
• Merck KGaA
• Sanofi
• Teva Pharmaceuticals
• Fujifilm Kyowa Kirin Biologics
• Samsung Bioepis
• Sun Pharmaceutical Industries

Competitive Landscape:

The competitive landscape in the global PPsoriatic Arthritis (PsA) Treatment market is intense, as leading pharmaceutical companies strive to innovate and expand their consumer base. Key players include AbbVie, Amgen, Pfizer, Novartis, Eli Lilly, and Janssen, all of which have invested substantially in R&D to develop advanced biologics and targeted therapies that improve treatment efficacy and reduce side effects. To maintain their positions, these companies are actively pursuing product differentiation by developing next-generation biologics, biosimilars, and personalized treatment options. This approach addresses specific patient needs and attracts a broader consumer base, particularly in regions with unique regulatory environments or healthcare priorities.

Strategic partnerships and collaborations are also critical to these companies’ market strategies. By forming alliances with research institutions and smaller biotech firms, large players can tap into new technological advancements and accelerate the commercialization of breakthrough therapies. Additionally, companies are expanding their geographic reach through mergers and acquisitions and by tailoring treatments to local market needs, especially in emerging regions such as Asia Pacific and Latin America.

Another common strategy is to increase awareness and accessibility by working closely with healthcare providers and governments to improve diagnostic rates and facilitate early intervention. In regions with stringent regulations, such as Europe, companies are adapting their marketing and compliance strategies to meet regional requirements, gaining a competitive edge by ensuring regulatory compliance and building trust with local healthcare systems. These combined strategies enable leading companies to sustain market dominance and drive PsA treatment adoption globally.

Recent Developments

• October 22, 2024: Alvotech and Teva Pharmaceuticals, which is an US affiliate of Teva Pharmaceutical Industries Ltd., announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. Following this development, the company strengthens its biosimilar development and enhanced the psoriatic arthritis treatment, as this is the second ustekinumab biosimilar to be approved by the FDA, following Amgens WEZLANA (ustekinumab-auub) in October 2023.
• September 23, 2024: UCB, which is a global biopharmaceutical company, announced it had received approval from the U.S. Food and Drug Administration (FDA) for a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of BIMZELX (bimekizumab-bkzx). On 27 December 2023, the company announced securing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for BIMZELX (bimekizumab) for the treatment of adults with psoriatic arthritis, non-radiographic axSpA (nr-axSpA), and ankylosing.

Frequently Asked Questions:

Q: What is the global PPsoriatic Arthritis (PsA) Treatment market size in 2024 and what is the projection for 2034?

A: The global PPsoriatic Arthritis (PsA) Treatment market size was calculated at USD 24.01 billion in 2024 and expected to reach USD 50.45 billion in 2034

Which regional market accounted for largest revenue share in 2023, and what is the expected trend over the forecast period?

A: North America is expected to account for largest revenue share in the global market over the forecast period.

Q: Which are the major companies are included in the global PPsoriatic Arthritis (PsA) Treatment market report?

A: Major companies in the market report are AbbVie Inc., Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Pfizer Inc., Bristol-Myers Squibb, Novartis AG, UCB S.A., Eli Lilly and Company, Biogen, Merck KGaA, Sanofi, Teva Pharmaceuticals, Fujifilm Kyowa Kirin Biologics, Samsung Bioepis, and Sun Pharmaceutical Industries​.

Q: What is the projected revenue CAGR of the global PPsoriatic Arthritis (PsA) Treatment market over the forecast period?

A: The global PPsoriatic Arthritis (PsA) Treatment market is expected to register a CAGR of 8.6% between 2025 and 2034.

Q: What are some key factors driving revenue growth of the PPsoriatic Arthritis (PsA) Treatment market ?

A: Some key factors driving market revenue growths are rising prevalence of arthritis, increasing patient awareness about the conditions and treatments, inclining demand for effective biologic and biosimilar therapies due to efficacy new therapies in managing PsA symptoms and slowing disease progression, and innovations in drug delivery.